Menu

Biosimilars/General

picture 111

Originator biologicals approved and marketed in Germany

Biosimilars/General | Posted 14/12/2012

Last updated: 14 December 2012 

The Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) is responsible for the approval, i.e. marketing authorization, of medicinal products, including biologicals, in Germany.

picture 94

Competing biosimilars to Amgen’s biologicals

Biosimilars/General | Posted 30/11/2012

Amgen has been a leading biotechnology company since 1980. Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology and launched the biotechnology industry’s first blockbuster medicines.

picture 82

ABPI issues position paper on biosimilars

Biosimilars/General | Posted 23/11/2012

The Association of the British Pharmaceutical Industry (ABPI), which represents innovative research-based biopharmaceutical companies in the UK, announced on 12 November 2012 the publication of its position paper on biosimilars.

picture 86

Biosimilars approved and marketed in Germany

Biosimilars/General | Posted 23/11/2012

Last updated: 23 November 2012 

The Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) is responsible for the approval, i.e. marketing authorization, of medicinal products, including biosimilars, in Germany.

picture 89

American dermatologists update position statement on biosimilar substitution

Biosimilars/General | Posted 16/11/2012

On 3 November 2012, the American Academy of Dermatology (AAD) updated its position statement on generics and biosimilar substitution to reflect its views, in particular on interchangeability* and naming of biosimilars.

picture 85

EMA definitions of generics and biosimilars

Biosimilars/General | Posted 21/10/2011

Confusion surrounding terms used in the global field of generics and biosimilars is a recognised problem. The members of the Biosimilar Medicinal Products Working Party at EMA have recently expressed the need to propose a more precise definition for biosimilars due to problems arising from imprecise usage of the term in the scientific literature and elsewhere [1].

picture 68

Biosimilars applications under review by EMA

Biosimilars/General | Posted 19/10/2012

Last update:  11 January 2013 

EMA is the body responsible for approval of biosimilars within the EU. A legal framework for approving biosimilars was established in 2003.  Approval of biosimilars is based on an abbreviated registration process, which allows biosimilars manufacturers to provide a reduced package of information compared to originator drugs, provided they can prove ‘similarity’ to the originator or ‘reference drug’.

picture 135

Teva asks FDA to delay approval of Biogen’s MS drug

Biosimilars/General | Posted 18/01/2013

Teva Pharmaceutical Industries (Teva) has petitioned FDA not to approve Biogen Idec’s (Biogen’s) investigational pill for treatment of multiple sclerosis, BG-12 (dimethyl fumarate), citing safety concerns.

picture52

EMA publishes revised biosimilar Q&A document for patients

Biosimilars/General | Posted 05/10/2012

On 27 September 2012 EMA published its revised Questions and Answers (Q&A) document on biosimilar medicines aimed at patients and the general public.

picture44

Naming and interchangeability of biosimilars raised in new survey

Biosimilars/General | Posted 05/10/2012

The contentious issues of naming and interchangeability of biosimilars in the US have been raised once again, as a result of a survey carried out by the Alliance for Safe Biologic Medicines (ASBM). The survey, released on 13 September 2012, examined physician practices and perspectives with regard to identification and substitution of biosimilars. These remain issues that are as yet unresolved by FDA.